Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07074886 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)
A Phase 2 study of Multiple Sclerosis, sponsored by Hoffmann-La Roche.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 182
- Enrollment target
- 20
- Study locations
NCT07074886: Recruiting Phase 2 study of Multiple Sclerosis, sponsored by Hoffmann-La Roche.
NCT07074886 is a Phase 2 study of Multiple Sclerosis that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 182 participants, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (69% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07074886, a Phase 2 study of Multiple Sclerosis, is actively recruiting participants, sponsored by Hoffmann-La Roche.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 182 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to assess the bioequivalence of ocrelizumab SC test formulation to the marketed ocrelizumab SC reference formulation in participants with either relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS). The study consists of 2 phases: a controlled phase, where participants in each group will receive one dose of test or reference formulation and a continuation phase, where all participants in both groups will receive ocrelizumab SC test formulation.
Conditions Studied
Interventions
- DRUG Ocrelizumab Test Formulation
- DRUG Ocrelizumab Reference Formulation
Study Locations (20)
Other
- IME - Instituto Médico Especializado - Buenos Aires
- Centro de Investigacion en Enfermedades Reumaticas CIER - Ciudad Autonoma Buenos Aires
- Sanatorio del Sur S.A. - San Miguel de Tucumán
- Charite - Universitätsmedizin Berlin - Berlin
Rio Grande do Sul
- Cpn - Centro de Pesquisa Neurologica Porto Alegre Ltda - Porto Alegre
- Núcleo de Pesquisa do Rio Grande do Sul - Porto Alegre
- Instituto do Cerebro do Rio Grande do Sul - Porto Alegre
California
- Profound Research, LLC - Carlsbad
Colorado
- Advanced Neurology of Colorado, LLC - Fort Collins
Florida
- Neurology Associates PA - Maitland
Tennessee
- Hope Neurology - Knoxville
Buenos Aires
- Centro de Especialidades Neurológicas y Rehabilitación - CENyR - CABA
CABA / Buenos Aires
- Focus CECIC - CABA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 182 participants |
| Start Date | 2025-11-13 |
| Est. Completion | 2030-10-30 |
| Phase | Phase 2 |
What NCT07074886 shows while recruiting
NCT07074886 is an interventional study that assigns participants to a tested intervention. The registered 182 participants enrollment target is mid-sized for trials with a published cap, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (69% lower).
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Ocrelizumab Test Formulation is the first listed.
NCT07074886 names 20 study sites across 15 states, led by Other, Rio Grande do Sul, California.
Frequently Asked Questions
What is clinical trial NCT07074886 about?
NCT07074886 is a clinical study titled "A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)". The main purpose of this study is to assess the bioequivalence of ocrelizumab SC test formulation to the marketed ocrelizumab SC reference formulation in participants with either relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS). The study consists of 2 phases: a co...
What is the current status of trial NCT07074886?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 182 participants. The study started on 2025-11-13. Estimated completion is 2030-10-30.
What conditions does trial NCT07074886 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
What interventions are being tested in trial NCT07074886?
The interventions under investigation include: Ocrelizumab Test Formulation (DRUG), Ocrelizumab Reference Formulation (DRUG).
Who is sponsoring clinical trial NCT07074886?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07074886 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Tennessee, Buenos Aires. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07074886's enrollment target sits among peer trials
182 82nd of 315 higher than 234 of 315 other Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype
RECRUITING · Phase 2
-
Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)
RECRUITING · Phase 2
-
Solriamfetol for the Treatment of Multiple Sclerosis Fatigue
RECRUITING · Phase 2
-
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
RECRUITING · Phase 2
-
Efficacy of Cognitive Behavioral Therapy for Insomnia to Treat Insomnia Symptoms in Individuals With Multiple Sclerosis
RECRUITING · Phase 2
-
A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03897998 · 182 participants · Phase 2
Neural Correlates of Hypoalgesia Driven by Observation
- NCT04300556 · 182 participants · Phase 1
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
- NCT04323735 · 182 participants · Phase 2
Intravesical Lactobacillus for Urinary Symptoms Among People With NLUTD Who Use Indwelling Catheters
- NCT05606731 · 182 participants · NA
Family Intervention to Prevent Childhood Obesity
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI